Abstract:
Objective This study aims to evaluate the roles of sentinel lymph node biopsy(SLNB)in patients with breast ductal carcinoma in situ(DCIS).
Methods The database of 13 multi-centers on 237 breast DCIS patients and 88 breast ductal carcinoma in situ with micro-invasion(DCISM)patients who received SLNB from January 2002 to May 2011 was retrospectively analyzed.
Results The sentinel lymph node(SLN)positive rate of the 325 patients was 6.15%.Among the 237 DCIS patients, the positive rate was 3.8%, and the rate was higher in patients with ultrasound-diagnosed large tumors or high histologic grade tumors.Among the 88 DCISM patients, the positive rate was 12.5%, and the rate was higher in younger DCISM patients.
Conclusion SLNB should be performed in all DCISM patients and in DCIS patients who received mastectomy.This procedure could be avoided in patients who received breast-conserving surgery. However, SLNB should be recommended to patients who have high risks for laboring invasive components.